论文部分内容阅读
目的:观察胃苏颗粒联合埃索美拉唑镁及伊托必利片治疗反流性食管炎的临床疗效。方法:92例反流性食管炎患者,随机分为实验组和对照组。对照组47例,予以埃索美拉唑镁及伊托必利片治疗;实验组45例在对照组治疗基础上,加用胃苏颗粒治疗。比较2组患者治疗前后的食管动力、主要症状积分和临床疗效。结果:实验组治疗4周后食管下括约肌(LES)静息压力和远端波幅显著高于对照组(P<0.05),胃食管反流病问卷(Gerd-Q)评分显著低于对照组(P<0.05)。2组治疗4周后吞咽成功率、体部障碍患病率比较,差异均有统计学意义(P<0.05)。治疗4周后实验组烧心、反酸和胸痛症状积分显著低于对照组(P<0.05)。内镜下临床总有效率实验组95.56%,对照组76.60%,2组比较,差异有统计学意义(P<0.05)。结论:胃苏颗粒联合埃索美拉唑镁及伊托必利片治疗反流性食管炎较单用西药治疗可更好改善食管动力和临床症状,临床疗效显著。
Objective: To observe the clinical effect of Weisu granule combined with esomeprazole magnesium and itopride on reflux esophagitis. Methods: 92 patients with reflux esophagitis were randomly divided into experimental group and control group. In the control group, 47 cases were treated with esomeprazole magnesium and itopride. In the experimental group, 45 cases were treated with the control group. The esophageal motility, main symptom scores and clinical efficacy before and after treatment in two groups were compared. Results: The resting pressure and distal amplitude of the lower esophageal sphincter (LES) in the experimental group after 4 weeks of treatment were significantly higher than those in the control group (P <0.05). The Gerd-Q score of the GES group was significantly lower than that of the control group P <0.05). The success rate of swallowing and the prevalence of body obstacle after 4 weeks of treatment in both groups were statistically significant (P <0.05). After 4 weeks of treatment, the scores of heartburn, acid reflux and chest pain in the experimental group were significantly lower than those in the control group (P <0.05). The total effective rate of endoscopic clinical experimental group 95.56%, 76.60% in the control group, the two groups, the difference was statistically significant (P <0.05). Conclusion: Weisu granule combined with esomeprazole magnesium and itopride tablets in the treatment of reflux esophagitis compared with the single Western medicine can better esophageal motility and clinical symptoms, the clinical curative effect is remarkable.